Locally Advanced Or Metastatic Solid Tumor clinical trials

Explore recruiting locally advanced or metastatic solid tumor clinical trials.

Recruiting locally advanced or metastatic solid tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Locally Advanced Or Metastatic Solid Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

TIRACAN; Open label phase 2 basket trial with Atezolizumab and Tiragolumab in solid tumors

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A study evaluating the safety, tolerability, pharmacokinetics, and activity of RO7566802 given alone and in combination with atezolizumab in patients with locally advanced or metastatic solid tumor malignancies

Spain, Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Spain, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

IL Believe: A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Belgium, Poland, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Locally Advanced Or Metastatic Solid Tumor trials by city

Locally Advanced Or Metastatic Solid Tumor in Toronto Locally Advanced Or Metastatic Solid Tumor in Vancouver Locally Advanced Or Metastatic Solid Tumor in Montreal Locally Advanced Or Metastatic Solid Tumor in Calgary Locally Advanced Or Metastatic Solid Tumor in Edmonton Locally Advanced Or Metastatic Solid Tumor in Ottawa Locally Advanced Or Metastatic Solid Tumor in Winnipeg Locally Advanced Or Metastatic Solid Tumor in Quebec City Locally Advanced Or Metastatic Solid Tumor in Hamilton Locally Advanced Or Metastatic Solid Tumor in Kitchener Locally Advanced Or Metastatic Solid Tumor in London Locally Advanced Or Metastatic Solid Tumor in Halifax Locally Advanced Or Metastatic Solid Tumor in New York Locally Advanced Or Metastatic Solid Tumor in Los Angeles Locally Advanced Or Metastatic Solid Tumor in Chicago Locally Advanced Or Metastatic Solid Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease